Is There Clear and Convincing Evidence of Cardiovascular Risk with Rosiglitazone?

被引：6

作者：

Kaul, S. ^{[1
,2
]}

Diamond, G. A. ^{[1
,2
]}

机构：

[1] Univ Calif Los Angeles, Cedars Sinai Med Ctr, Div Cardiol, Los Angeles, CA 90048 USA

[2] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90048 USA

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2011年 / 89卷 / 06期

关键词：

MYOCARDIAL-INFARCTION; DEATH; ASSOCIATION;

D O I：

10.1038/clpt.2011.65

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

[No abstract available]

引用

页码：773 / 776

页数：4

共 10 条

[1]

[Anonymous], JOINT M END MET DRUG

[2] Analytical Issues Regarding Rosiglitazone Meta-analysis [J].

Claggett, Brian ;

Wei, Lee-Jen .

ARCHIVES OF INTERNAL MEDICINE, 2011, 171 (02) :179-180

[3] Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death [J].

Diamond, George A. ;

Bax, Leon ;

Kaul, Sanjay .

ANNALS OF INTERNAL MEDICINE, 2007, 147 (08) :578-581

[4] Risk of Acute Myocardial Infarction, Stroke, Heart Failure, and Death in Elderly Medicare Patients Treated With Rosiglitazone or Pioglitazone [J].

Graham, David J. ;

Ouellet-Hellstrom, Rita ;

MaCurdy, Thomas E. ;

Ali, Farzana ;

Sholley, Christopher ;

Worrall, Christopher ;

Kelman, Jeffrey A. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2010, 304 (04) :411-418

[5] DIABETES Breaking news! Rosiglitazone and cardiovascular risk [J].

Kaul, Sanjay ;

Diamond, George A. .

NATURE REVIEWS CARDIOLOGY, 2010, 7 (12) :670-672

[6] Thiazolidinedione Drugs and Cardiovascular Risks A Science Advisory From the American Heart Association and American College of Cardiology Foundation [J].

Kaul, Sanjay ;

Bolger, Ann F. ;

Herrington, David ;

Giugliano, Robert P. ;

Eckel, Robert H. .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2010, 55 (17) :1885-1894

[7] Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes [J].

Nathan, David M. ;

Buse, John B. ;

Davidson, Mayer B. ;

Ferrannini, Ele ;

Holman, Rury R. ;

Sherwin, Robert ;

Zinman, Bernard .

DIABETES CARE, 2009, 32 (01) :193-203

[8] Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes (vol 356, pg 2457, 2007) [J].

Nissen, Steven E. ;

Wolski, Kathy .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (24) :2457-2471

[9] Rosiglitazone Revisited An Updated Meta-analysis of Risk for Myocardial Infarction and Cardiovascular Mortality [J].

Nissen, Steven E. ;

Wolski, Kathy .

ARCHIVES OF INTERNAL MEDICINE, 2010, 170 (14) :1191-1201

[10]

US FDA, 2010, ADV COMM M NDA 21071

← 1 →